title: Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis.
abstract: Severe alpha-1-antitrypsin deficiency is the only proven genetic risk factor for chronic obstructive pulmonary disease (COPD). We have assembled a cohort of 44 probands with severe, early-onset COPD, who do not have severe alpha-1-antitrypsin deficiency. A surprisingly high prevalence of females (79.6%) was found. Assessment of the risk to relatives of these early-onset COPD probands for airflow obstruction and chronic bronchitis was performed to determine whether significant familial aggregation for COPD, independent of alpha-1-antitrypsin deficiency, could be demonstrated. First- degree relatives of early-onset COPD probands had significantly lower FEV1 and FEV1/FVC values than control subjects (p < 0.01), despite similar pack-years of smoking. Reduced spirometric values in first-degree relatives of early-onset COPD probands were found only in current or ex-cigarette smokers. The mean FEV1 in current or ex-smoking first-degree relatives was 76.1 +/- 20.9% predicted compared to 89.2 +/- 14.4% predicted in current or ex-smoking control subjects (p < 0.01); in lifelong nonsmokers, the mean FEV1 was 93.4% predicted for both control subjects and first-degree relatives of early-onset COPD probands. Generalized estimating equations, adjusting for age and pack-years of smoking, demonstrated increased odds of reduced FEV1 and chronic bronchitis in current or ex-smoking first-degree relatives of early-onset COPD probands. Using a new method to estimate relative risk from relative odds, we estimate that the relative risks for FEV1 below 60%, FEV1 below 80%, and chronic bronchitis are each approximately three in current or ex-smoking first-degree relatives of early-onset COPD probands. The increased risk to relatives of early-onset COPD probands for reduced FEV1 and chronic bronchitis, limited to current or ex-smokers, suggests genetic risk factor(s) for COPD that are expressed in response to cigarette smoking.
authors.affiliation: Channing Laboratory, Brigham and Women's Hospital, Boston, MA 02115, USA. ed.silverman@channing.harvard.edu
authors.forename: E K
authors.initials: EK
authors.lastname: Silverman
authors.forename: H A
authors.initials: HA
authors.lastname: Chapman
authors.forename: J M
authors.initials: JM
authors.lastname: Drazen
authors.forename: S T
authors.initials: ST
authors.lastname: Weiss
authors.forename: B
authors.initials: B
authors.lastname: Rosner
authors.forename: E J
authors.initials: EJ
authors.lastname: Campbell
authors.forename: W J
authors.initials: WJ
authors.lastname: O'DONNELL
authors.forename: J J
authors.initials: JJ
authors.lastname: Reilly
authors.forename: L
authors.initials: L
authors.lastname: Ginns
authors.forename: S
authors.initials: S
authors.lastname: Mentzer
authors.forename: J
authors.initials: J
authors.lastname: Wain
authors.forename: F E
authors.initials: FE
authors.lastname: Speizer
mesh_terms: D001991:Bronchitis / Q000209:etiology / Q000235:genetics; D002908:Chronic Disease; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000209:etiology / Q000235:genetics* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D014797:Vital Capacity; D019896:alpha 1-Antitrypsin Deficiency / Q000150:complications